Manchester scoring system
| Cancer and patient age | BRCA1 | BRCA2 |
| FBC <30 | 6 | 5 |
| FBC 30–39 | 4 | 4 |
| FBC 40–49 | 3 | 3 |
| FBC 50–59 | 2 | 2 |
| FBC>59 | 1 | 1 |
| MBC <60 | 5 (if BRCA2 tested); for combined, score = 5 without prior testing | 8 |
| MBC >59 | 5 (if BRCA2 tested); for combined, score = 5 without prior testing | 5 |
| Ovarian cancer <60 | 8 | 5 (if BRCA1 tested); for combined, score = 5 without prior testing |
| Ovarian cancer >59 | 5 | 5 (if BRCA1 tested); for combined, score = 5 without prior testing |
| Pancreatic cancer | 0 | 1 |
| Prostate cancer <60 | 0 | 2 |
| Prostate cancer >59 | 0 | 1 |
Scores are added for each cancer in a direct blood lineage (cancers on the same side of the family). The combined score is determined by adding both the BRCA1 and BRCA2 scores without consideration for prior testing, thus MBC scores 5 points for BRCA1, and ovarian cancer 5 for BRCA2. A combined score of 16 points can be used as a 10% threshold, and 20 points as a 20% threshold in non-founder Western populations. In families with no unaffected females, a lower threshold could be used. Other tumour types such as cholangiocarcinoma and ocular melanoma can contribute to the BRCA2 score, but the numbers of these tumours is too low to validate a precise score.
FBC, female breast cancer; MBC, male breast cancer.